Human Genetics

, Volume 121, Issue 3–4, pp 401–411 | Cite as

Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease

  • Pamela A. McCaskie
  • John P. Beilby
  • Caroline M. L. Chapman
  • Joseph Hung
  • Brendan M. McQuillan
  • Peter L. Thompson
  • Lyle J. Palmer
Original Investigation


High-density lipoprotein cholesterol (HDL-C) is a known inverse predictor of coronary heart disease (CHD) and is thus a potential therapeutic target. Cholesteryl ester transfer protein (CETP) is a key protein in HDL-C metabolism such that elevated CETP activity is associated with lower HDL-C. Currently available HDL-C raising drugs are relatively ineffective and evidence suggesting the role of CETP in HDL-C levels has promoted the development of CETP inhibitors as potential therapeutic agents for CHD. We investigated three SNPs in the CETP gene in two cross-sectional community-based populations (n = 1,574 and 1,109) and a population of 556 CHD patients to determine if reduced CETP activity due to genetic variations in the CETP gene would increase HDL-C levels and reduce the risk of CHD. CETP genotypes and haplotypes were tested for association with lipid levels, CETP activity and risk of CHD. Multivariate analysis showed the common AAB2 haplotype defined by the G-2708A, C-629A and TaqIB polymorphisms, was consistently associated with reduced CETP activity and increased HDL-C levels. A mean increase in HDL-C levels of 0.16–0.24 mmol/l was observed in individuals with two copies of the AAB2 haplotype relative to non AAB2 carriers across all three populations (P < 0.001). A case-control study of males indicated no association between single SNPs or haplotypes and the risk of CHD. These results suggest that raising HDL-C via CETP inhibition may not alter risk of CHD. Randomized control trials are needed to determine whether CETP inhibition will in reality reduce risk of CHD by raising HDL-C.


  1. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG (2000) Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: the Copenhagen City heart study. Circulation 102:2197–2203PubMedGoogle Scholar
  2. Akey J, Jin L, Xiong M (2001) Haplotypes vs single marker linkage disequilibrium tests: what do we gain? Eur J Hum Genet 9:291–300PubMedCrossRefGoogle Scholar
  3. Ansell BJ, Navab M, Watson KE, Fonarow GC, Fogelman AM (2004) Anti-inflammatory properties of HDL. Rev Endocr Metab Disord 5:351–358PubMedCrossRefGoogle Scholar
  4. Barter P, Kastelein J, Nunn A, Hobbs R (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168:195–211PubMedCrossRefGoogle Scholar
  5. Barter PJ, Kastelein JJP (2006) Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am College Cardiol 47:492–499CrossRefGoogle Scholar
  6. Bauerfeind A, Knoblauch H, Schuster H, Luft FC, Reich JG (2002) Single nucleotide polymorphism haplotypes in the cholesteryl-ester transfer protein (CETP) gene and lipid phenotypes. Hum Hered 54:166–173PubMedCrossRefGoogle Scholar
  7. Blankenberg S, Rupprecht HJ, Bickel C, Jiang XC, Poirier O, Lackner KJ, Meyer J, Cambien F, Tiret L (2003) Common genetic variation of the cholesteryl ester transfer protein gene strongly predicts future cardiovascular death in patients with coronary artery disease. J Am Coll Cardiol 41:1983–1989PubMedCrossRefGoogle Scholar
  8. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, Cambien F, Nicaud V, de Grooth GJ, Talmud PJ, Humphries SE, Miller GJ, Eiriksdottir G, Gudnason V, Kauma H, Kakko S, Savolainen MJ, Arca M, Montali A, Liu S, Lanz HJ, Zwinderman AH, Kuivenhoven JA, Kastelein JJ (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111:278–287PubMedCrossRefGoogle Scholar
  9. Boekholdt SM, Thompson JF (2003) Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res 44:1080–1093PubMedCrossRefGoogle Scholar
  10. Borggreve SE, Hillege HL, Wolffenbuttel BH, de Jong PE, Bakker SJ, van der Steege G, van Tol A, Dullaart RP (2005) The effect of cholesteryl ester transfer protein -629C ≥ A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. J Clin Endocrinol Metab 90:4198–204PubMedCrossRefGoogle Scholar
  11. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, van der Steege G, van Tol A, Dullaart RPF, on behalf of the PREVEND Study Group (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91:3382–3388Google Scholar
  12. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, et al (1989) Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 342:448–451PubMedCrossRefGoogle Scholar
  13. Carter KW, McCaskie PA, Palmer LJ (2006) JLIN: a java based linkage disequilibrium plotter. BMC Bioinformatics 7:60PubMedCrossRefGoogle Scholar
  14. Chapman CM, Palmer LJ, McQuillan BM, Hung J, Burley J, Hunt C, Thompson PL, Beilby JP (2001) Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population. Atherosclerosis 159:209–217PubMedCrossRefGoogle Scholar
  15. Clark RW (2006) Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol Cardiavasc Renal 6:162–168CrossRefGoogle Scholar
  16. Dachet C, Poirier O, Cambien F, Chapman J, Rouis M (2000) New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol 20:507–515PubMedGoogle Scholar
  17. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22PubMedCrossRefGoogle Scholar
  18. de Grooth GJ, Klerkx AH, Stroes ES, Stalenhoef AF, Kastelein JJ, Kuivenhoven JA (2004) A review of CETP and its relation to atherosclerosis. J Lipid Res 45:1967–1774PubMedCrossRefGoogle Scholar
  19. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V (2001) The -629C > A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. Atherosclerosis 159:187–192PubMedCrossRefGoogle Scholar
  20. Forrester JS, Makkar R, Shah PK (2005) Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111:1847–1854PubMedCrossRefGoogle Scholar
  21. Fumeron F, Betoulle D, Luc G, Behague I, Ricard S, Poirier O, Jemaa R, Evans A, Arveiler D, Marques-Vidal P et al (1995) Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction. J Clin Invest 96:1664–1771PubMedCrossRefGoogle Scholar
  22. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8–15PubMedGoogle Scholar
  23. Gudnason V, Kakko S, Nicaud V, Savolainen MJ, Kesaniemi YA, Tahvanainen E, Humphries S (1999) Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group. Eur J Clin Invest 29:116–128PubMedCrossRefGoogle Scholar
  24. Guo SW, Thompson EA (1992) Performing the exact test of Hardy–Weinberg proportion for multiple alleles. Biometrics 48:361–372PubMedCrossRefGoogle Scholar
  25. Hirano K, Yamashita S, Nakajima N, Arai T, Maruyama T, Yoshida Y, Ishigami M, Sakai N, Kameda-Takemura K, Matsuzawa Y (1997) Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity. Arterioscler Thromb Vasc Biol 17:1053–1059PubMedGoogle Scholar
  26. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H (2002) Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (Lond) 103:587–594Google Scholar
  27. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR (1990a) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234–1238CrossRefGoogle Scholar
  28. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR (1990b) Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234–1238CrossRefGoogle Scholar
  29. Kakko S, Tamminen M, Paivansalo M, Kauma H, Rantala AO, Lilja M, Reunanen A, Kesaniemi YA, Savolainen MJ (2001) Variation at the cholesteryl ester transfer protein gene in relation to plasma high density lipoproteins cholesterol levels and carotid intima-media thickness. Eur J Clin Invest 31:593–602PubMedCrossRefGoogle Scholar
  30. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA (2003) Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C ≥ A polymorphism and a novel promoter variant are independently associated with CETP concentration. Hum Mol Genet 12:111–123PubMedCrossRefGoogle Scholar
  31. Knoblauch H, Bauerfeind A, Krahenbuhl C, Daury A, Rohde K, Bejanin S, Essioux L, Schuster H, Luft FC, Reich JG (2002) Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum Mol Genet 11:1477–1485PubMedCrossRefGoogle Scholar
  32. Knoblauch H, Bauerfeind A, Toliat MR, Becker C, Luganskaja T, Gunther UP, Rohde K, Schuster H, Junghans C, Luft FC, Nurnberg P, Reich JG (2004) Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 13:993–1004PubMedCrossRefGoogle Scholar
  33. Le Goff W, Guerin M, Petit L, Chapman MJ, Thillet J (2003) Regulation of human CETP gene expression: role of SP1 and SP3 transcription factors at promoter sites −690, −629, and −37. J Lipid Res 44:1322–1331PubMedCrossRefGoogle Scholar
  34. Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, Ridker PM (2002) A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis 161:469–474PubMedCrossRefGoogle Scholar
  35. Lu H, Inazu A, Moriyama Y, Higashikata T, Kawashiri MA, Yu W, Huang Z, Okamura T, Mabuchi H (2003) Haplotype analyses of cholesteryl ester transfer protein gene promoter: a clue to an unsolved mystery of TaqIB polymorphism. J Mol Med 81:246–255PubMedGoogle Scholar
  36. Lusis AJ (2003) Genetic factors in cardiovascular disease. 10 questions. Trends Cardiovasc Med 13:309–316PubMedCrossRefGoogle Scholar
  37. McCaskie PA, Cadby G, Hung J, McQuillan BM, Chapman CM, Carter KW, Thompson PL, Palmer LJ, Beilby JP (2006) The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. Clin Genet 70:114–121PubMedCrossRefGoogle Scholar
  38. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J (1999) Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 99:2383–2388PubMedGoogle Scholar
  39. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H (2000) A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. 406:203–207Google Scholar
  40. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW (1999) A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 341:718–724PubMedCrossRefGoogle Scholar
  41. Ordovas JM (2000) Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): should we be measuring them? Clin Chem Lab Med 38:945–949PubMedCrossRefGoogle Scholar
  42. Rust S, Funke H, Assmann G (1993) Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection. Nucleic Acids Res 21:3623–3629PubMedCrossRefGoogle Scholar
  43. Slatkin M, Excoffier L (1996) Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 76(Pt4):377–383PubMedGoogle Scholar
  44. Tobin MD, Braund PS, Burton PR, Thompson JR, Steeds R, Channer K, Cheng S, Lindpaintner K, Samani NJ (2004) Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur Heart J 25:459–467PubMedCrossRefGoogle Scholar
  45. Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesaniemi YA (1994) DNA polymorphisms at the locus for human cholesteryl ester transfer protein (CETP) are associated with macro- and microangiopathy in non-insulin-dependent diabetes mellitus. Clin Genet 46:217–227PubMedCrossRefGoogle Scholar
  46. Winkelmann BR, Hoffmann MM, Nauck M, Kumar AM, Nandabalan K, Judson RS, Boehm BO, Tall AR, Ruano G, Marz W (2003) Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy. Pharmacogenom J 3:284–296CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Pamela A. McCaskie
    • 1
  • John P. Beilby
    • 2
    • 3
  • Caroline M. L. Chapman
    • 2
  • Joseph Hung
    • 4
    • 5
  • Brendan M. McQuillan
    • 4
    • 5
  • Peter L. Thompson
    • 3
    • 4
  • Lyle J. Palmer
    • 1
    • 5
  1. 1.Laboratory for Genetic Epidemiology, Western Australian Institute for Medical Research, UWA Centre for Medical ResearchUniversity of Western AustraliaNedlandsAustralia
  2. 2.Clinical BiochemistryPathWest, Laboratory Medicine Western AustralianPerthAustralia
  3. 3.School of Surgery and PathologyUniversity of Western AustraliaPerthAustralia
  4. 4.Sir Charles Gairdner Hospital Campus of the Heart Research Institute of Western AustraliaPerthAustralia
  5. 5.School of Medicine and PharmacologyUniversity of Western AustraliaPerthAustralia

Personalised recommendations